Pembrolizumab Plus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up

Post time 2024-4-19 14:43:21

journal：Journal of Thoracic Oncology

Authors：Shirish M. Gadgeel; Delvys Rodríguez-Abreu; Balazs Halmos; Marina C. Garassino; Takayasu Kurata; Ying Cheng; Erin Jensen; Mark Shamoun; Kumar Rajagopalan; Luis Paz-Ares

Published date：2024-4-

DOI：10.1016/j.jtho.2024.04.011

PDF link：https://www.sciencedirect.com/sc ... 556086424001692/pdf

Article link：http://dx.doi.org/10.1016/j.jtho.2024.04.011

Article Source：Elsevier BV。

Remark：

Post time 2024-4-19 14:43:22

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Pembrolizumab Plus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Pembrolizumab Plus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Pembrolizumab Plus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up